nascobal (r) (b 12) demand is strong

Quote






























right right right

and one reason watson blew q 2 was they foolishlt put toprol in reve estimates for april- june period


wrong wrong wrong

and toprol is difficlut very difficult to mgf and their fla plant has had serious quality problems


((((((((((((((((((((((((THINK $20)))))))))))))))))))))))))
 






Watson now admitting metoprolol succ. approval is for 25 and 50 mg ONLY with 100 and 200 LATER

They also noted it is difficult to mfg and remember their fla plant has a history of problems. Meanwhile par chugs along with no competition in q3 in the generic space and if watson gets approval they will only have 25 and 50. Watson was wrong before as they estimated toprol sales in q2 AND IT DID NOT HAPPEN


((((((((((($20+++SOON))))))))))))
 






p cos right again

TOPROL AND AG UP 320% TO $298M IN LATEST 3 MONTHS


US sales of the Toprol-XL product range, which includes sales of the authorised generic, increased by 320
percent in the second quarter to $298 million. Total prescriptions for the franchise more than doubled. Pipeline
filling of the authorised generic product following a return to full supply and price changes accounted for the
balance of the sales growth. The two generic competitor products remain off the US market, and it remains
difficult to ascertain when or if these products will return to the market or when potential new entrants may be
approved.
• Toprol-XL franchise sales in the US in the first half were up 251 percent to $474 million.
 












Anonymous said:
p cos right again

TOPROL AND AG UP 320% TO $298M IN LATEST 3 MONTHS


US sales of the Toprol-XL product range, which includes sales of the authorised generic, increased by 320
percent in the second quarter to $298 million. Total prescriptions for the franchise more than doubled. Pipeline
filling of the authorised generic product following a return to full supply and price changes accounted for the
balance of the sales growth. The two generic competitor products remain off the US market, and it remains
difficult to ascertain when or if these products will return to the market or when potential new entrants may be
approved.
• Toprol-XL franchise sales in the US in the first half were up 251 percent to $474 million.
Click to expand...

awesome
 


















YES THEY WILL AND YES YOU ARE RIGHT



TRADES AT A MEASLY 4X ANNUAL CASH FLOW 7 second(s) ago They generated a buck a share in POSITVE CASH FLW IN Q1 AND WILL DO BETTER TOMORROW


since bosshog claims he knows so much, how about a few peers trading at 4 times annual cash flow?

i guarantee you he can't find any

none zilch

(((((((((((((((((((((((((((((THINK $20++)))))))))))))))))))))))))

Sentiment : Strong Buy
 












Why the surprise about watson as i reported here weeks ago they were ready willing and able?

And i was not surprised about pat's strong confidence in nacobal

Remember that generic succinate has captured only 50% of toprol family so even with watson there is potential and watson has approval for only 2 strengths

Today was a buying opportunity BIG TIME as we all forget about cash flow, the balance sheet and that potent branded/ first to file pipeline


((((((($$ twenty soon)))))))
 




































Top Bottom
Back
Quote